BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases

(NYSE:BDX) Becton, Dickinson and Company announced that its Board of Directors has declared a quarterly dividend of $1.06 per common share. This dividend represents an increase of 1.0% from the previous quarter. The dividend will be payable on December 31, 2026, to holders of record as of December 10, 2026. The indicated annual dividend rate is $4.24 per share. The Board has also authorized the company to repurchase up to 10 million shares of BD common stock, in addition to shares remaining under the previous 2026 authorization. The share repurchase authorizations allow the company to buy back shares through open market purchases, privately negotiated transactions, or other methods. The actual timing, manner, number, and value of any shares repurchased will be determined by management at its discretion, based on factors such as the market price of BD's common stock, general market and economic conditions, and other business considerations. Tom Polen, chairman, CEO and president of BD, stated that this marks the 55th consecutive fiscal year in which BD has raised its dividend. He noted that this achievement maintains BD's membership in the S&P 500 Dividend Aristocrats Index, which tracks companies that have increased dividends for at least 25 consecutive years. Polen also commented that the dividend increase and new share repurchase authorization reflect the company's confidence in its long-term outlook. He emphasized BD's ongoing commitment to creating value through its New BD strategy and returning capital to shareholders. BD operates globally with more than 60,000 employees. The company delivers billions of products annually that impact global healthcare.

BD Names Bridget Bagnato Worldwide President of Peripheral Intervention

(NYSE:BDX) Becton, Dickinson and Company (BD) announced the appointment of Bridget Bagnato as worldwide president of its Peripheral Intervention business unit, effective November 16. Bagnato will be responsible for driving the global strategic, operational, and commercial performance of the Peripheral Intervention business unit. She will report directly to Peter Menziuso, who is the executive vice president and president of the Interventional segment. The Peripheral Intervention business unit is headquartered in Tempe, Arizona. Peter Menziuso stated that Bagnato brings deep experience across BD and a strong understanding of customers, with a proven ability to grow businesses through innovation and operational excellence. Menziuso expressed confidence that Bagnato will build on Peripheral Intervention's strong foundation and advance differentiated technologies across peripheral vascular disease, oncology, and end-stage kidney disease. Bagnato currently serves as worldwide president of BD's Specimen Management business unit. She has been with BD for more than 27 years and has held leadership roles in various BD businesses, including Medication Delivery Solutions and Surgery. In the Surgery business, she served as vice president and general manager of Surgical Complication Solutions. Bagnato holds a bachelor's degree from Villanova University. She also holds an MBA from The Fuqua School of Business at Duke University. BD is described as one of the world's largest pure-play medical technology companies. The company operates globally with more than 60,000 employees. BD delivers billions of products annually that impact global healthcare. The company focuses on advancing innovation across medical essentials, connected care, biopharma systems, and interventional technologies.

BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options

(NYSE:BDX) Becton, Dickinson and Company (BD) announced the U.S. commercial launch of the BD® Liverty™ TIPS Stent Graft, a next-generation transjugular intrahepatic portosystemic shunt (TIPS) system. The Liverty™ TIPS Stent Graft is designed to provide physicians with deployment accuracy and control, as well as flexibility to tailor treatment based on individual patient anatomy, disease progression, and clinical goals. The product enters the U.S. market with established clinical and physician experience in Europe. The launch is supported by six-month interim results from the 177 patient, prospective, multi-center ARCH clinical study, which is the first and only IDE study with small TIPS diameter (6-7 mm) clinical data. The Liverty™ TIPS Stent Graft is now commercially available in the U.S. and is intended for use in patients with complications of portal hypertension, such as internal bleeding or fluid buildup in the abdomen. TIPS procedures, including those using the Liverty™ TIPS Stent Graft, are used to manage conditions such as variceal bleeding and refractory ascites. The device features an expandable diameter design (6-10 mm) to address patient-specific hemodynamics. Covered stent lengths range from 4 to 10 cm, making it the longest commercially available TIPS stent graft. The system includes a fully sheathed, tri-axial delivery system designed for deployment accuracy, control, and ease-of-use. It also features highly visible radiopaque markers and a marker band to aid in visualization and accurate placement under fluoroscopy. The delivery system allows for sheath-less tracking through the liver parenchyma. Rob Righi, vice president and general manager of the Vascular Platform, Peripheral Intervention at BD, stated that the system helps physicians make real-time treatment decisions for patients with complications of portal hypertension by offering the longest length TIPS stent graft on the market and tailored shunt diameter sizing. Dr. Ziv Haskal, principal investigator of the ARCH trial and professor of radiology and surgery at the University of Virginia, highlighted the unique ease of delivering and controlling the device during deployment, as well as its ability to accommodate a new range of intended TIPS diameters and longer lengths. The U.S. commercial availability of the Liverty™ TIPS Stent Graft expands BD's interventional portfolio and reinforces the company's commitment to advancing treatment options for patients with complications of portal hypertension.

Arthur Hu to Join BD as Chief Information and Digital Officer

(NYSE:BDX) Becton, Dickinson and Company (BD) announced the appointment of Arthur (Art) Hu as executive vice president and chief information and digital officer, effective September 30. Art Hu brings over 25 years of experience in global technology, digital, and business transformation initiatives. He previously served as senior vice president, global chief information officer, and chief technology and delivery officer for the Solutions and Services Group at Lenovo Group. At Lenovo, Hu led digital technology, AI adoption, and business transformation across customer, partner, and employee-facing platforms. Prior to Lenovo, Hu spent more than a decade at McKinsey & Company, advising organizations on technology, operations, strategy, and organizational transformation. Tom Polen, chairman, CEO, and president of BD, stated that Art Hu is an exceptional technology and transformation leader with a proven track record of using digital, AI, and automation to drive performance at scale. Polen emphasized that Hu's experience will strengthen BD's leadership team and provide an advantage as technology becomes more central to healthcare delivery and MedTech operations. Art Hu will be responsible for modernizing BD's enterprise, embedding AI into operations, and translating technology into innovation and stronger business outcomes. Denise Russell Fleming, the current executive vice president and chief information and digital officer, will retire from BD at the end of 2026. BD operates globally with more than 60,000 employees. The company delivers billions of products annually that impact global healthcare. BD focuses on advancing health by driving innovation across medical essentials, connected care, biopharma systems, and interventional solutions. The company collaborates closely with customers to enhance outcomes, lower costs, increase clinical efficiency, improve safety, and expand access to healthcare.

BD Appoints Gary Sorsher as Chief Quality Officer; Jeff Silvestri to Retire

(NYSE: BDX) BD (Becton, Dickinson and Company) announced that Gary Sorsher has been named executive vice president and chief quality officer, effective September 8. Sorsher brings more than 30 years of experience leading quality organizations across world-class MedTech companies. The company also announced that Jeffrey (Jeff) Silvestri, senior vice president, global head of quality, will retire from BD in October after more than 25 years. Since joining BD in 1998, Silvestri has helped strengthen BD's quality foundation and advance quality capabilities across the enterprise. BD operates across the globe, with more than 60,000 employees. BD delivers billions of products annually that have a positive impact on global healthcare.

EMS and BD expand access to GLP-1 therapies in Brazil with semaglutide launch

(NYSE: BDX) BD (Becton, Dickinson and Company) and EMS announced their collaboration in the launch of a semaglutide therapy in Brazil. BD is described as one of the world's largest pure-play medical technology companies, operating across the globe with more than 60,000 employees. EMS is stated to be one of Brazil's leading pharmaceutical companies, with more than 60 years of experience and a global footprint spanning more than 60 countries. The semaglutide therapy utilizes BD's established injection pen platform, specifically the BD Vystra™ Injection Pen platform. The collaboration aims to address healthcare challenges associated with chronic diseases, including obesity and type 2 diabetes. EMS continues to invest in advanced manufacturing and R&D, including peptide capabilities to support GLP 1 therapies. The BD Vystra™ Injection Pen platform is highlighted as supporting scalable solutions to meet rising demand for injectable therapies.

Mike Garrison to Retire from BD

(NYSE: BDX) BD (Becton, Dickinson and Company) announced that Dr. Michael (Mike) Garrison has informed the company of his intent to retire after more than 20 years with BD, effective Oct. 2. Garrison is currently executive vice president and president of the Medical Essentials and BioPharma Systems segments at BD. During his tenure, Garrison held several leadership roles including executive vice president and president of BD's Medical segment, worldwide president of Medication Management Solutions and worldwide president of Surgery. BD operates across the globe, with more than 60,000 employees, and delivers billions of products annually. A comprehensive search is underway to identify the next president of Medical Essentials. Going forward, BioPharma Systems will report directly to Tom Polen, Chairman, CEO and President of BD, streamlining the operating model. The company describes itself as one of the world's largest pure-play medical technology companies.

BD Awarded Vizient Innovative Technology Contract for CentroVena One™ Insertion System

(NYSE: BDX) BD (Becton, Dickinson and Company) announced that its BD® CentroVena One™ Insertion System has been awarded an Innovative Technology contract from Vizient®. The contract was awarded following a review by hospital experts serving on Vizient's client-led councils. The CentroVena One™ Insertion System is the first and only all-in-one central venous catheter insertion system designed to simplify central line placement and enhance patient safety. The system streamlines workflow and reduces procedural complexity with 30% fewer steps and a 50% reduction in maximum procedure time compared to standard techniques. Vizient represents a client base with a portfolio that represents more than $156 billion in annual purchasing volume. BD operates across the globe with more than 60,000 employees and delivers billions of products annually. The company supports those on the frontlines of healthcare by developing transformative technologies, services and solutions.

Peter Menziuso Named EVP and President, BD Interventional

BD (Becton, Dickinson and Company) (NYSE: BDX) announced that Peter Menziuso has been named executive vice president and president, BD Interventional, effective June 1. Menziuso brings more than 30 years of global healthcare leadership experience and most recently served as Company Group Chairman of Johnson & Johnson Vision, where he led a $5 billion global business. BD is described as one of the world's largest pure-play medical technology companies, operating across the globe with more than 60,000 employees and delivering billions of products annually. The company emphasizes its commitment to advancing the world of health by driving innovation across medical essentials, connected care, biopharma systems, and interventional. BD supports healthcare frontlines by developing transformative technologies, services, and solutions to optimize clinical operations and improve patient care. The appointment is positioned as a move to accelerate execution and deliver continued growth for BD Interventional. Investors are encouraged to visit bd.com or connect via LinkedIn, X, or Instagram for more information.

BD Reimagines Central Line Insertion, Advancing Leadership in Patient Safety Through Breakthrough Vascular Access Technology

BD (Becton, Dickinson and Company) (NYSE: BDX) announced the commercial launch of the BD® CentroVena One™ Insertion System, the first all-in-one central venous catheter (CVC) insertion device on the market. The system is designed to simplify central line placement for clinicians and enhance patient safety by streamlining key steps and incorporating safety-focused design elements. CentroVena One™ is now commercially available in the U.S. and has received U.S. FDA 510(k) clearance and acceptance into the FDA Safer Technologies Program (STeP). The system aims to reduce workflow steps by 30% and insertion time by 50% compared to the current standard of care.

BD Board Declares Dividend

The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX) announced a quarterly dividend of $1.05 per common share. The dividend is payable on June 30, 2026, to holders of record on June 9, 2026. The indicated annual dividend rate is $4.20 per share. BD is described as one of the world's largest pure-play medical technology companies, operating globally with more than 60,000 employees. This announcement is significant for investors as it provides details on dividend payments and highlights the company's scale and impact.